Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale.

• Rachel C Graham, Richard A. C. Hughes
• Journal of neurology, neurosurgery, and…
• 2006

A new peripheral neuropathy activities measure, the Overall Neuropathy Limitations Scale (ONLS), was derived by modifying the Overall Disability Sum Score (ODSS) slightly. Its inter-rater reliability… (More)

Guillain-Barré syndrome

• Richard A. C. Hughes, David Reid Cornblath
• The Lancet
• 2005

Guillain-Barré syndrome consists of at least four subtypes of acute peripheral neuropathy. Major advances have been made in understanding the mechanisms of some of the subtypes. The histological… (More)

Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.

• Robert D.M. Hadden, David Reid Cornblath, +4 authors Anthony V. Swan
• Annals of neurology
• 1998

We performed electrophysiological and serological testing within 15 days of symptom onset on 369 patients with Guillain-Barré Syndrome (GBS) enrolled in a trial comparing plasma exchange, intravenous… (More)

Clinical and epidemiologic features of Guillain-Barré syndrome.

• Richard A. C. Hughes, J Harrison Rees
• The Journal of infectious diseases
• 1997

Guillain-Barré syndrome (GBS) is defined clinically as a peripheral neuropathy causing limb weakness that progresses for up to 4 weeks before reaching a plateau. The symptoms may be caused by… (More)

Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial

• Richard A. C. Hughes, Peter D. Donofrio, +7 authors Pieter Antoon van Doorn
• The Lancet Neurology
• 2008

BACKGROUND Short-term studies suggest that intravenous immunoglobulin might reduce disability caused by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) but long-term effects have not… (More)

119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands

• Jessica E. Hoogendijk, Anthony A. Amato, +6 authors Richard A. C. Hughes
• Neuromuscular Disorders
• 2004

The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis.

• Basil Sharrack, Richard A. C. Hughes
• Multiple sclerosis
• 1999

A postal survey showed that the majority of 49 leading international neurologists involved with multiple sclerosis research felt that currently existing outcome measures for this illness were… (More)

Pathogenesis of Guillain–Barré syndrome

• Richard A. C. Hughes, Rob D. M. Hadden, Norman A. Gregson, Kenneth J. Smith
• Journal of Neuroimmunology
• 1999

Recent neurophysiological and pathological studies have led to a reclassification of the diseases that underlie Guillain-Barré syndrome (GBS) into acute inflammatory demyelinating… (More)

Corticosteroids for Guillain-Barré syndrome.

• Richard A. C. Hughes, Anthony V. Swan, Rinske van Koningsveld, Pieter Antoon van Doorn
• The Cochrane database of systematic reviews
• 2006

BACKGROUND The cause of Guillain-Barré syndrome is inflammation of the peripheral nerves, which corticosteroids would be expected to benefit. OBJECTIVES To examine the ability of corticosteroids to… (More)

A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee.

• Richard A. C. Hughes, Andrew Carr
• Rheumatology
• 2002

OBJECTIVES A randomized, placebo-controlled, double-blind trial of the relative effectiveness of glucosamine sulphate and placebo in managing pain in osteoarthritis (OA) of the knee. METHODS Eighty… (More)

• ‹
• 1
• 2
• 3
• 4
• 5
• ›